Screener
Immix Biopharma, Inc. IMMX Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Deferred offering costs | 164,723 | 93,630 |
| Right-of-use asset, net | 927,728 | 966,917 |
| Property and equipment, net | 2,428,377 | 2,521,621 |
| Total assets | $95,816,057 | $104,840,341 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $10,414,266 | $9,971,207 |
| Operating lease liability - current | 125,392 | 139,339 |
Document
FAQ
- What is Immix Biopharma, Inc.'s total assets?
- Immix Biopharma, Inc. (IMMX) reported total assets of $95.82M in Q1 2026.
- How has Immix Biopharma, Inc.'s total assets changed year-over-year?
- Immix Biopharma, Inc.'s total assets increased by 381.7% year-over-year, from $19.89M to $95.82M.
- What is the long-term trend for Immix Biopharma, Inc.'s total assets?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s total assets has grown at a 186.9% compound annual growth rate (CAGR), from $539.6K to $104.84M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Immix Biopharma, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude